X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Torrent Pharma with Lupin Ltd - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

TORRENT PHARMA vs LUPIN LTD - Comparison Results

TORRENT PHARMA    Change

Torrent Pharmaceuticals Ltd. is the flagship company of the Torrent Group set up in 1959. Based in Ahmedabad, it was promoted by Mr U.N. Mehta initially as Trinity Laboratories Ltd. and was later renamed to its current name. The company derives its r... More

LUPIN LTD 
   Change

Lupin is a leading pharmaceutical company with a strong presence in anti-infective, cardiovascular and asthma. Apart from having a strong domestic presence, the company markets its products in the regulated markets of the US and Europe and semi-regul... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    TORRENT PHARMA LUPIN LTD TORRENT PHARMA/
LUPIN LTD
 
P/E (TTM) x 28.5 20.1 141.6% View Chart
P/BV x 5.4 2.7 198.7% View Chart
Dividend Yield % 1.0 0.9 109.4%  

Financials

 TORRENT PHARMA   LUPIN LTD
EQUITY SHARE DATA
    TORRENT PHARMA
Mar-17
LUPIN LTD
Mar-17
TORRENT PHARMA/
LUPIN LTD
5-Yr Chart
Click to enlarge
High Rs1,7681,750 101.0%   
Low Rs1,1861,384 85.7%   
Sales per share (Unadj.) Rs346.1387.4 89.3%  
Earnings per share (Unadj.) Rs55.256.6 97.4%  
Cash flow per share (Unadj.) Rs73.376.8 95.4%  
Dividends per share (Unadj.) Rs14.007.50 186.7%  
Dividend yield (eoy) %0.90.5 198.0%  
Book value per share (Unadj.) Rs257.1298.9 86.0%  
Shares outstanding (eoy) m169.22451.58 37.5%   
Bonus/Rights/Conversions -ESOPS-  
Price / Sales ratio x4.34.0 105.5%   
Avg P/E ratio x26.827.7 96.8%  
P/CF ratio (eoy) x20.120.4 98.8%  
Price / Book Value ratio x5.75.2 109.6%  
Dividend payout %25.413.2 191.6%   
Avg Mkt Cap Rs m249,887707,513 35.3%   
No. of employees `00011.816.8 70.2%   
Total wages/salary Rs m9,93428,495 34.9%   
Avg. sales/employee Rs Th4,971.510,418.3 47.7%   
Avg. wages/employee Rs Th843.21,697.0 49.7%   
Avg. net profit/employee Rs Th792.41,523.0 52.0%   
INCOME DATA
Net Sales Rs m58,569174,943 33.5%  
Other income Rs m2,2331,065 209.7%   
Total revenues Rs m60,802176,008 34.5%   
Gross profit Rs m13,77344,931 30.7%  
Depreciation Rs m3,0699,122 33.6%   
Interest Rs m2,0561,525 134.8%   
Profit before tax Rs m10,88135,349 30.8%   
Minority Interest Rs m0-72 0.0%   
Prior Period Items Rs m083 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,5459,785 15.8%   
Profit after tax Rs m9,33625,575 36.5%  
Gross profit margin %23.525.7 91.6%  
Effective tax rate %14.227.7 51.3%   
Net profit margin %15.914.6 109.0%  
BALANCE SHEET DATA
Current assets Rs m53,841119,542 45.0%   
Current liabilities Rs m31,61261,206 51.6%   
Net working cap to sales %38.033.3 113.8%  
Current ratio x1.72.0 87.2%  
Inventory Days Days9776 127.9%  
Debtors Days Days8490 93.2%  
Net fixed assets Rs m42,079131,660 32.0%   
Share capital Rs m846903 93.7%   
"Free" reserves Rs m42,655134,073 31.8%   
Net worth Rs m43,501134,976 32.2%   
Long term debt Rs m22,40856,478 39.7%   
Total assets Rs m101,250266,073 38.1%  
Interest coverage x6.324.2 26.0%   
Debt to equity ratio x0.50.4 123.1%  
Sales to assets ratio x0.60.7 88.0%   
Return on assets %11.310.2 110.5%  
Return on equity %21.518.9 113.3%  
Return on capital %19.619.3 101.9%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m20,06681,885 24.5%   
Fx outflow Rs m5,30421,506 24.7%   
Net fx Rs m14,76260,378 24.4%   
CASH FLOW
From Operations Rs m10,12741,148 24.6%  
From Investments Rs m-7,869-25,287 31.1%  
From Financial Activity Rs m-1,9184,332 -44.3%  
Net Cashflow Rs m21220,193 1.0%  

Share Holding

Indian Promoters % 71.5 46.6 153.4%  
Foreign collaborators % 0.0 0.2 -  
Indian inst/Mut Fund % 7.0 11.3 62.1%  
FIIs % 12.6 31.9 39.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 8.8 10.1 87.1%  
Shareholders   26,511 98,259 27.0%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare TORRENT PHARMA With:   NOVARTIS  JUBILANT LIFE SCIENCES  BIOCON LTD  STERLING BIOTECH  NATCO PHARMA  

Compare TORRENT PHARMA With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Weak Start to the Week; PSU & Metal Stocks Fall(Closing)

Indian share markets continued to witness selling pressure in the afternoon session as benchmark Sensex slipped below the 34,000-mark.

Related Views on News

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Lupin: US Markets Drags down Revenues and Net Profits (Quarterly Results Update - Detailed)

Nov 2, 2017

Domestic markets registers robust growth in the quarter

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Lupin: Decline in US Business Impacts Overall Growth (Quarterly Results Update - Detailed)

May 29, 2017

Currency fluctuation and one time provision impacts operating margins.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

More Views on News

Most Popular

Here's What You Should Do in this Market Crash(The 5 Minute Wrapup)

Feb 6, 2018

The market correction has provided a golden opportunity to buy five high-quality safe stocks.

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

When Small is Not Always Beautiful(Chart Of The Day)

Feb 6, 2018

Big companies enjoying tax deductions and exemptions have an edge over the small companies.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

TORRENT PHARMA SHARE PRICE


Feb 19, 2018 (Close)

TRACK TORRENT PHARMA

  • Track your investment in TORRENT PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON TORRENT PHARMA

TORRENT PHARMA 5-YR ANALYSIS

COMPARE TORRENT PHARMA WITH

MARKET STATS